共 50 条
- [21] Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic LeukemiaBLOOD, 2017, 130Rogers, Kerry A.Huang, YingStark, AmyAwan, Farrukh T.Maddocks, Kami J.Woyach, Jennifer A.Whitlow, ThomasByrd, John C.Jones, Jeffrey A.
- [22] Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell MalignanciesBLOOD, 2016, 128 (22)Salles, Gilles A.Morschhauser, FranckCheson, BruceRule, Simon A.Fegan, ChristopherGuillaume, CartronNelson, CaraYang, YingsiMitra, SiddharthaStarodub, AlexanderDyer, Martin J. S.
- [23] Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b StudyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : E443 - E451Palomba, M. LiaTill, Brian G.Park, Steven I.Morschhauser, FranckCartron, GuillaumeMarks, ReinhardShivhare, MaheshHong, Wan-JenRaval, AparnaChang, Alice C.Penuel, EliciaPopplewell, Leslie L.
- [24] Phase 1b/2 study of tivozanib in combination with durvalumab in subjects with advanced hepatocellular carcinoma (Deductive): Efficacy results in previously untreated patientsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)Iyer, Renuka V.Li, DanengDayyani, FarshidRowe, Julie HaewonBeg, Muhammad ShaalanKasturi, VijayAbrams, Thomas Adam
- [25] Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk MyelofibrosisBLOOD, 2017, 130Couban, StephenBenevolo, GiuliaDonnellan, WilliamCultrera, JenniferKoschmieder, SteffenVerstovsek, SrdanHooper, GregoryHertig, ChristianTandon, ManeeshDimier, NatalieTempleton, IanPassamonti, Francesco
- [26] Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naive higher-risk myelodysplastic syndromes.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Fong, Chun YewWei, Andrew H.Frattini, Mark G.Jacoby, MeaganBorate, UmaGotze, Katharina S.Garcia, Jacqueline SuenPollyea, Daniel AaronHoles, LeanneZhou, YingFakouhi, Kaffa MussumehLeverson, JoelHarb, Jason G.Agarwal, Suresh K.Attarchi, FaranehMabry, Mack H.Hong, Wan-JenJahn, Thomas MichaelFenaux, PierreGarcia-Manero, Guillermo
- [27] Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b StudyBLOOD, 2014, 124 (21)Berdeja, JesusJagannath, SundarZonder, JeffreyBadros, AshrafKaufman, Jonathan L.Manges, RobertLynch, MarkBleickardt, EricPaliwal, PrashniVij, Ravi
- [28] Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid LeukemiaBLOOD, 2016, 128 (22)Walker, Alison R.Bhatnagar, BhavanaMarcondes, A. Mario Q.DiPaolo, JulieVasu, SumithraMims, Alice S.Klisovic, Rebecca B.Walsh, Katherine J.Canning, ReneeBehbehani, Gregory K.Garzon, RamiroBlachly, James S.Johnson, Amy J.Abella-Dominicis, EstebanByrd, John C.Blum, William
- [29] ANX005, a C1q inhibitor, for treatment of Guillain-Barre Syndrome: Phase 1b study resultsJOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2020, 25 (04) : 508 - 509Papri, NowshinIslam, ZhahirulJahan, IsratKroon, Henk-AndreHumphriss, EricSankaranarayanan, SethuArtis, DeanYednock, TedKeswani, SanjayAzad, Khan Abul KalamMohammad, Quazi Deen
- [30] ANX005, A C1Q INHIBITOR, FOR TREATMENT OF GUILLAIN-BARRE SYNDROME: PHASE 1B STUDY RESULTSMUSCLE & NERVE, 2020, 62 : S97 - S97Papri, NowshinIslam, ZhahirulJahan, IsratKroon, Henk-AndreHumphriss, EricSankaranarayanan, SethuArtis, Dean R.Yednock, TedKeswani, SanjayAzad, Khan Abul KalamMohammad, Quazi Deen